SK Chemicals Signs Exclusive Sales and Distribution Agreement for 'Acerison' with Mothers Pharmaceutical

The Nation's First Aceclofenac and Eperisone Combination Drug

Acerison Tablets developed by Mothers Pharmaceutical and distributed and sold by SK Chemicals.
[Photo by SK Chemicals]

[Asia Economy Reporter Lee Gwan-joo] SK Chemicals announced on the 5th that it has signed an exclusive sales and distribution agreement with Mothers Pharmaceutical for 'Acerison,' the first domestic combination drug of aceclofenac and eperisone.

Acerison tablets are a combination of the non-steroidal anti-inflammatory drug (NSAID) aceclofenac and the muscle relaxant eperisone, approved for pain relief in patients with acute low back pain accompanied by musculoskeletal muscle spasms.

According to the pharmaceutical market research firm UBIST, as of last year, aceclofenac, an anti-inflammatory analgesic, had a market size of 93.5 billion KRW, and eperisone, a muscle relaxant, had a market size of 69 billion KRW. These two ingredients, commonly used together for patients with muscle pain and spasm symptoms, also rank first in combination usage according to UBIST.

Six companies, including Mothers Pharmaceutical, have been preparing for joint development of combination drugs, and in September, six products including Acerison were approved and launched on the 1st of this month with drug price listing.

Kim Jwajin, CEO of Mothers Pharmaceutical, said, "We expect to significantly expand the market through collaboration between Mothers Pharmaceutical's development and SK Chemicals, which is leading the musculoskeletal market in sales and distribution."

Park Hyun-sun, Head of Pharma Planning at SK Chemicals, said, "Acerison tablets are one of the first combination drugs of NSAIDs and muscle relaxants launched domestically," adding, "As SK Chemicals leads the musculoskeletal disease market through Joins and others, we expect synergy in the sales of Acerison as well."

This content was produced with the assistance of AI translation services.